We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Outsourcing Drug Development Increasingly Global

By LabMedica International staff writers
Posted on 03 Nov 2008
Fueled by rising market pressures, companies are increasingly outsourcing the drug development process. More...
In the United States, not only the complexity of conducting clinical trials has grown over the last 20 years, but also the number of drugs in development increased, government regulations tightened, and patient recruitment became more difficult.

A new report from Kalorama Information (New York, NY, USA), an international market research company, revealed that in 2007 34% of global research and development spending, or US$26.4 billion, was committed to outsourcing, up from 22% in 2002, an increasing amount of which is going offshore.

Developing and bringing a drug to market costs over $900 million and takes as long as 15 years, whereas over 80% of drugs that enter clinical trials fail to be approved by the U.S. Food and Drug Administration (FDA). Now, in order to decrease research and development (R&D) expenses and accelerate drug discovery and development, developers are outsourcing more of their R&D functions. However, a key obstacle remains--the patient recruitment and retention process--particularly as clinical trial protocols become more complicated, delays can result in millions of dollars of lost sales.

In response, the outsourcing trend has begun to move offshore as drug developers seek patient recruitment in large populations of people eager to take part in clinical trial research, especially in Eastern Europe, Asia, and Latin America. These regions can often produce the required number of participants in half the time, with better compliance and less expensive medical professionals.

"Pharmaceutical marketing is truly global right now,” noted Kalorama Information's publisher Bruce Carlson. "Developers need to submit new drugs for approval in multiple countries simultaneously, rather than in succession, in order to maximize revenue and reduce costs. Recruiting volunteers in multiple countries is essential.”

Currently, however, the United States remains the world's largest clinical research market with just over half of all worldwide trial sites still located there.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of research services.

Related Links:

Kalorama Information



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.